Size of drug patent thickets highlighted by report, amidst intense pharma IP scrutiny
A new report revealing the large number of secondary patents granted, and applied for, by the owners of the US' best-selling drugs is sure to fuel the ongoing controversy over pharma IP rights.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.